ERBB receptors and cancer: the complexity of targeted inhibitors (Q29619520)

Europe PubMed Central

title

ERBB receptors and cancer: the complexity of targeted inhibitors (English)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15864276

30 April 2017

author name string

Hynes NE

series ordinal

1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15864276

30 April 2017

Lane HA

series ordinal

2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15864276

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15864276

30 April 2017

language of work or name

1 reference

30 April 2017

publication date

May 2005

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15864276

30 April 2017

published in

Nature Reviews Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15864276

30 April 2017

volume

5

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15864276

30 April 2017

issue

5

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15864276

30 April 2017

page(s)

341-54

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15864276

Untangling the ErbB signalling network

30 April 2017

cites work

1 reference

The ErbB signaling network: receptor heterodimerization in development and cancer

1 May 2017

1 reference

The STATs of cancer--new molecular targets come of age

1 May 2017

1 reference

The TOR pathway: a target for cancer therapy

1 May 2017

1 reference

Epidermal growth factor-related peptides and their receptors in human malignancies

1 May 2017

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 May 2017

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 May 2017

1 reference

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 May 2017

1 reference

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors

1 May 2017

1 reference

Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha

1 May 2017

1 reference

Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains

1 May 2017

1 reference

EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization

1 May 2017

1 reference

The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors

1 May 2017

1 reference

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

1 May 2017

1 reference

EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF

1 May 2017

1 reference

A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor.

1 May 2017

1 reference

TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells

1 May 2017

1 reference

Phosphorylation-dependent interactions between ADAM15 cytoplasmic domain and Src family protein-tyrosine kinases

1 May 2017

1 reference

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 May 2017

1 reference

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 May 2017

1 reference

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 May 2017

1 reference

1 May 2017

The Hallmarks of Cancer

1 reference

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 May 2017

1 reference

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival

1 May 2017

1 reference

PTEN: one gene, many syndromes

1 May 2017

1 reference

High frequency of mutations of the PIK3CA gene in human cancers

1 May 2017

1 reference

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

1 May 2017

1 reference

Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 AND PKC-delta

1 May 2017

1 reference

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

1 May 2017

1 reference

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 May 2017

1 reference

Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor

1 May 2017

1 reference

Multiple essential functions of neuregulin in development

1 May 2017

1 reference

Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes

1 May 2017

1 reference

Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors

1 May 2017

1 reference

Specificity within the EGF family/ErbB receptor family signaling network

1 May 2017

1 reference

Common and distinct elements in cellular signaling via EGF and FGF receptors

31 March 2020

1 reference

ErbB receptors: directing key signaling networks throughout life

31 March 2020

1 reference

Muc4/Sialomucin Complex, the Intramembrane ErbB2 Ligand, Translocates ErbB2 to the Apical Surface in Polarized Epithelial Cells

31 March 2020

1 reference

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

31 March 2020

1 reference

Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo

31 March 2020

1 reference

c-Src and cooperating partners in human cancer

31 March 2020

1 reference

The discovery of receptor tyrosine kinases: targets for cancer therapy

31 March 2020

1 reference

Genetic pathways to glioblastoma: a population-based study

31 March 2020

1 reference

Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma

31 March 2020

1 reference

Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails

31 March 2020

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

31 March 2020

1 reference

Lung cancer: intragenic ERBB2 kinase mutations in tumours

31 March 2020

1 reference

Structure of the extracellular region of HER3 reveals an interdomain tether

31 March 2020

1 reference

31 March 2020

1 reference

Neuregulins: functions, forms, and signaling strategies

31 March 2020

1 reference

TACE is required for the activation of the EGFR by TGF-alpha in tumors

31 March 2020

1 reference

Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors

31 March 2020

1 reference

Regulation of tyrosine kinase cascades by G-protein-coupled receptors.

31 March 2020

1 reference

Lipid rafts identified as locations of ectodomain shedding mediated by Meltrin beta/ADAM19.

31 March 2020

1 reference

Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells.

31 March 2020

1 reference

Proximal events in signaling by plasma membrane estrogen receptors

31 March 2020

1 reference

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

31 March 2020

1 reference

Not so strange bedfellows: G-protein-coupled receptors and Src family kinases

31 March 2020

1 reference

The ADAMs family of metalloproteases: multidomain proteins with multiple functions

31 March 2020

1 reference

Activation of pp60c-src protein kinase activity in human colon carcinoma

31 March 2020

1 reference

Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice

31 March 2020

1 reference

ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency

31 March 2020

1 reference

Clinical translation of angiogenesis inhibitors

31 March 2020

1 reference

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

31 March 2020

1 reference

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

31 March 2020

1 reference

Gefitinib--a novel targeted approach to treating cancer

31 March 2020

1 reference

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

31 March 2020

1 reference

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

31 March 2020

1 reference

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

31 March 2020

1 reference

Micronutrient sprinkles to control childhood anaemia

31 March 2020

1 reference

The development and clinical use of trastuzumab (Herceptin).

31 March 2020

1 reference

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

31 March 2020

1 reference

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

31 March 2020

1 reference

Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects

31 March 2020

1 reference

The GH-IGF-I axis and breast cancer.

31 March 2020

1 reference

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

31 March 2020

1 reference

Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells

31 March 2020

1 reference

P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

31 March 2020

1 reference

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

31 March 2020

1 reference

31 March 2020

Putting the rap on Akt.

1 reference

Tumour suppressors hamartin and tuberin: intracellular signalling

31 March 2020

1 reference

Mammalian target of rapamycin (mTOR) Inhibitors

31 March 2020

1 reference

Cooperation between fibroblast growth factor receptor-4 and ErbB2 in regulation of cyclin D1 translation

31 March 2020

1 reference

Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers

31 March 2020

1 reference

Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells

31 March 2020

1 reference

Akt kinases in breast cancer and the results of adjuvant therapy

31 March 2020

1 reference

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

31 March 2020

1 reference

Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells

31 March 2020

1 reference

Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective

31 March 2020

1 reference

Aromatase inhibitors in breast cancer

31 March 2020

1 reference

Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance

31 March 2020

1 reference

17 beta-estradiol mimics ligand activity of the c-erbB2 protooncogene product

31 March 2020

1 reference

Overcoming endocrine therapy resistance by signal transduction inhibition

31 March 2020

1 reference

The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro

31 March 2020

1 reference

Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer

31 March 2020

1 reference

Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase

31 March 2020

1 reference

Endocrine-responsive breast cancer and strategies for combating resistance

31 March 2020

1 reference

Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation

31 March 2020

1 reference

HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study

31 March 2020

1 reference

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

31 March 2020

1 reference

Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma.

31 March 2020

1 reference

Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice

31 March 2020

1 reference

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

31 March 2020

1 reference

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

31 March 2020

1 reference

Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow

31 March 2020

1 reference

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors

31 March 2020

1 reference

Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents.

31 March 2020

1 reference

Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer

31 March 2020

1 reference

Targeting the mitogen-activated protein kinase cascade to treat cancer

31 March 2020

1 reference

Switching on kinases: oncogenic activation of BRAF and the PDGFR family

31 March 2020

1 reference

Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors

31 March 2020

1 reference

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity

31 March 2020

1 reference

Epidermal growth factor receptor: mechanisms of activation and signalling.

31 March 2020

1 reference

Multiple ErbB-2/Neu Phosphorylation Sites Mediate Transformation through Distinct Effector Proteins.

31 March 2020

1 reference

Memo mediates ErbB2-driven cell motility.

31 March 2020

1 reference

Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein

31 March 2020

1 reference

Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers

31 March 2020

1 reference

Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas

31 March 2020

1 reference

PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization

31 March 2020

1 reference

Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor

31 March 2020

1 reference

Strain-dependent epithelial defects in mice lacking the EGF receptor

31 March 2020

1 reference

Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype

31 March 2020

1 reference

Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor

31 March 2020

1 reference

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

31 March 2020

1 reference

Interstitial lung disease associated with drug therapy

31 March 2020

1 reference

Severe acute interstitial pnuemonia and gefitinib

31 March 2020

1 reference

Requirement for neuregulin receptor erbB2 in neural and cardiac development

31 March 2020

1 reference

ErbB2 is essential in the prevention of dilated cardiomyopathy.

31 March 2020

1 reference

Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin).

31 March 2020

1 reference

Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor

31 March 2020

1 reference

Humanization of an anti-p185HER2 antibody for human cancer therapy

31 March 2020

1 reference

A mutant epidermal growth factor receptor with defective protein tyrosine kinase is unable to stimulate proto-oncogene expression and DNA synthesis

31 March 2020

1 reference

Tyrosine kinases as targets in cancer therapy - successes and failures

31 March 2020

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15864276

31 March 2020

Identifiers

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017

Dimensions Publication ID

1049655893

0 references

1 reference

Consolidated OpenCitations Corpus – April 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=15864276

PubMed publication ID

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017